Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyclacel CEO Explains How Sapacitabine Might Get Cleared For AML, Despite Phase III Failure

Executive Summary

The company will talk to regulators in the US and Europe to see if the drug could be considered in elderly patients with low baseline peripheral white blood cells, who fared better than others in the failed SEAMLESS study.

You may also be interested in...



FDA Hold On Seattle Genetics' Trials Clouds CD33's Suitability for AML

FDA has placed clinical holds on several Phase I trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia after four patients died, clouding a field that is still in the shadow of Pfizer's failed Mylotarg.

Novartis's Midostaurin To Fill 30 Year Void In AML Treatment

First Phase III data for Novartis AG's acute myeloid leukemia (AML) therapy midostaurin has hematologists excited as the drug "inches forward" towards a market approval – opening up the door for possible evolution of standard of care for AML patients, which has been sealed shut for the past 30 years.

Cyclacel Continues AML Trial Of Sapacitabine Despite Futility Analysis

The oncology biotech is plowing ahead with its late-stage study of sapacitabine, despite unfavorable findings during an interim analysis.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel